BOSTON, January 8, 2025: Morgan Lewis represented uniQure N.V. in its approximately $75 million underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share.
uniQure is advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.
Partners Ben Stein and Tim Corbett and associates Anna Voremberg Ellement and Shabeena Sharak advised uniQure.